See the DrugPatentWatch profile for delstrigo
Delstrigo is a combination antiretroviral medication used to treat HIV-1 infection in adults and adolescents. It contains three active ingredients: doravirine, lamivudine, and tenofovir disoproxil fumarate [1]. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) [2].
What is Delstrigo approved for?
Delstrigo is approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35 kg [1]. It is indicated as a complete regimen for patients not on antiretroviral therapy for HIV-1 infection or as a replacement for a stable antiretroviral regimen in patients who are virologically suppressed [3].
How does Delstrigo work?
Delstrigo works by inhibiting the replication of the HIV-1 virus. Doravirine blocks the activity of reverse transcriptase, an enzyme that HIV needs to convert its RNA into DNA and integrate it into the host cell's DNA. Lamivudine and tenofovir disoproxil fumarate are also reverse transcriptase inhibitors that work by terminating DNA synthesis [2].
When does Delstrigo's patent expire?
Information regarding specific patent expiry dates for Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) can be found on DrugPatentWatch.com. Patent protection is crucial for pharmaceutical companies as it grants a period of market exclusivity [4].
What are the potential side effects of Delstrigo?
Common side effects associated with Delstrigo include dizziness, nausea, diarrhea, fatigue, and headache [1]. More serious but less common side effects can include liver problems, and lactic acidosis [3]. Patients should consult with their healthcare provider for a comprehensive list of potential side effects and to discuss any concerns [3].
How does Delstrigo compare to other HIV medications?
Delstrigo is a single-tablet regimen, offering convenience for patients. Its active ingredients are also available in other HIV treatments, but the specific combination and dosage in Delstrigo are designed for its indicated use [2]. Comparisons to other HIV medications would depend on factors like efficacy, side effect profiles, drug interactions, and patient adherence [4].
Can generic versions of Delstrigo be made?
The availability of generic versions of Delstrigo depends on patent expiry and any other exclusivity periods granted by regulatory agencies. Once patents expire, other manufacturers can seek approval to produce generic versions of the drug [4].
What is the pricing of Delstrigo?
The price of Delstrigo can vary significantly based on factors such as insurance coverage, pharmacy, and location. For specific pricing information, individuals should consult with their healthcare provider or pharmacist [4].
Who manufactures Delstrigo?
Delstrigo is manufactured by Merck [1].
Sources:
[1] https://www.merck.com/product/delstrigo-prescribing-information.pdf
[2] https://www.drugpatentwatch.com/drug/delstrigo
[3] https://www.delstrigo.com/
[4] https://www.drugpatentwatch.com